The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

The Africa Centre Disease Control (CDC), with global health partners, has announced the launch of a "pivotal" clinical trial ...

Emergent Biosolutions (NYSE:EBS) stock rose 14% post-market Wednesday after the company raised the lower end of its revenue ...

Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.